{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:35:20Z","timestamp":1787668520042,"version":"build-2736575974"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases.<\/jats:p>","DOI":"10.3389\/fmed.2022.906565","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T06:58:31Z","timestamp":1655189911000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?"],"prefix":"10.3389","volume":"9","author":[{"given":"Sheila","family":"Bermejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Bolufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Riveiro-Barciela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B2","unstructured":"1592020"},{"key":"B3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.acr.2019.03.002","article-title":"From immune checkpoints to vaccines: the past, present and future of cancer immunotherapy","volume":"143","author":"Osipov","year":"2019","journal-title":"Adv Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"103169","DOI":"10.1016\/j.critrevonc.2020.103169","article-title":"Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: a systematic review of the literature","volume":"157","author":"Mroue","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1007\/s00262-021-02983-8","article-title":"Immune checkpoint inhibitors-induced nephropathy: a French national survey","volume":"70","author":"G\u00e9rard","year":"2021","journal-title":"Cancer Immunol Immunother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e000467","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/ckj\/sfaa008","article-title":"Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience","volume":"14","author":"Oleas","year":"2021","journal-title":"Clin Kidney J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/gfab034","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors","volume":"4","author":"Garc\u00eda-Carro","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J Immunother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: a report of 2 cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","volume":"17","author":"Jung","year":"2016","journal-title":"BMC Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ekir.2018.10.017","article-title":"Immune check point inhibitor\u2013associated glomerulonephritis","volume":"4","author":"Ashour","year":"2019","journal-title":"Kidney Int Reports."},{"key":"B25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody\u2013induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor\u2013associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Reports"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/1759-7714.13405","article-title":"Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events","volume":"11","author":"Zheng","year":"2020","journal-title":"Thorac Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.34067\/KID.0001072019","article-title":"Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor\u2013associated acute kidney injury: PRO","volume":"1","author":"Perazella","year":"2020","journal-title":"Kidney360."},{"key":"B32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"530","DOI":"10.34067\/KID.0000232022","article-title":"The role of kidney biopsy in Immune Checkpoint Inhibitor-associated AKI","volume":"3","author":"Rashidi","year":"2022","journal-title":"Kidney360"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e127456","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight"},{"key":"B35","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.ajkd.2014.12.013","article-title":"Cancer incidence among US medicare ESRD patients receiving hemodialysis, 1996-2009","volume":"65","author":"Butler","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.2018.7260","article-title":"Representation of patients with chronic kidney disease in trials of cancer therapy","volume":"319","author":"Kitchlu","year":"2018","journal-title":"JAMA."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2147\/DDDT.S167077","article-title":"Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies","volume":"12","author":"Sui","year":"2018","journal-title":"Drug Des Devel Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1053\/j.ajkd.2020.02.451","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients on dialysis: a retrospective case series","volume":"76","author":"Strohbehn","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"584834","DOI":"10.3389\/fonc.2020.584834","article-title":"Safety and efficacy of immune checkpoint inhibitors for patients with metastatic urothelial carcinoma and end-stage renal disease: experiences from real-world practice","volume":"10","author":"Kuo","year":"2020","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e903","DOI":"10.1016\/j.clgc.2019.06.009","article-title":"Immunotherapy in dialysis-dependent cancer patients: our experience in patients with metastatic renal cell carcinoma and a review of the literature","volume":"17","author":"Vitale","year":"2019","journal-title":"Clin Genitourin Cancer."},{"key":"B43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.34067\/KID.0000422020","article-title":"Use of immune checkpoint inhibitors in end stage kidney disease patients, single center experience and review of the literature","volume":"1","author":"Hirsch","year":"2020","journal-title":"Kidney360."},{"key":"B44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/CJI.0000000000000327","article-title":"Evaluation of checkpoint inhibitors in cancer patients with end-stage renal disease on hemodialysis: case series and review of the literature","volume":"43","author":"Jain","year":"2020","journal-title":"J Immunother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.1016\/j.clgc.2019.04.004","article-title":"Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma and end-stage renal disease at 2 centers","volume":"17","author":"Tachibana","year":"2019","journal-title":"Clin Genitourin Cancer."},{"key":"B46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12979-018-0131-x","article-title":"A comprehensive characterization of aggravated aging-related changes in T lymphocytes and monocytes in end-stage renal disease: the iESRD study","volume":"15","author":"Chiu","year":"2018","journal-title":"Immun Ageing"},{"key":"B47","first-page":"191","volume-title":"Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab. Vol. 376, The New England journal of medicine","author":"Barnett","year":"2017"},{"key":"B48","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.ajkd.2018.12.011","article-title":"Mortality in incident maintenance dialysis patients versus incident solid organ cancer patients: a population-based cohort","volume":"73","author":"Naylor","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1681\/ASN.2015040373","article-title":"Variation in cancer incidence among patients with esrd during kidney function and nonfunction intervals","volume":"27","author":"Yanik","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.12.015","article-title":"US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"67","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"a015677","DOI":"10.1101\/cshperspect.a015677","article-title":"Cancer in the transplant recipient","volume":"3","author":"Chapman","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1111\/ajt.15495","article-title":"Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer","volume":"19","author":"Engels","year":"2019","journal-title":"Am J Transplant."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1111\/ajt.15954","article-title":"Transplant-associated cancer in the era of immune checkpoint inhibitors: Primum non nocere","volume":"20","author":"Zwald","year":"2020","journal-title":"Am J Transplant."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","volume":"20","author":"d'Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"key":"B56","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ekir.2019.11.015","article-title":"Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients","volume":"5","author":"Manohar","year":"2020","journal-title":"Kidney Int Reports."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.nephro.2019.05.006","article-title":"Toxicit\u00e9s r\u00e9nales des inhibiteurs des points de contr\u00f4le de l'auto-immunit\u00e9","volume":"16","author":"Izzedine","year":"2020","journal-title":"N\u00e9phrologie and Th\u00e9rapeutique."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1056\/NEJMc1813976","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Cruzado","year":"2018","journal-title":"N Engl J Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/TP.0000000000003292","article-title":"Immune checkpoint inhibitors in transplantation - a case series and comprehensive review of current knowledge","volume":"105","author":"Delyon","year":"2021","journal-title":"Transplantation"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00262-020-02644-2","article-title":"Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy","volume":"69","author":"Danesh","year":"2020","journal-title":"Cancer Immunol Immunother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J."},{"key":"B67","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ndt\/gfw382","article-title":"Renal effects of immune checkpoint inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrol Dial Transplant."},{"key":"B68","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","article-title":"Renal complications of immune checkpoint blockade","volume":"41","author":"Murakami","year":"2017","journal-title":"Curr Probl Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-019-02321-z","article-title":"Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer","volume":"68","author":"Kehl","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"130","DOI":"10.34067\/KID.0000852019","article-title":"Immune checkpoint inhibitor nephrotoxicity: update 2020","volume":"1","author":"Gupta","year":"2020","journal-title":"Kidney360."},{"key":"B71","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.clim.2019.06.005","article-title":"Urine macrophages reflect kidney macrophage content during acute tubular interstitial and glomerular injury","volume":"205","author":"Sun","year":"2019","journal-title":"Clin Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.3390\/jcm10132986","article-title":"Urinary cytokines reflect renal inflammation in acute tubulointerstitial nephritis: a multiplex bead-based assay assessment","volume":"10","author":"Valenzuela","year":"2021","journal-title":"J Clin Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Reports."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.2215\/CJN.00920121","article-title":"Gene expression profiling in kidney transplants with immune checkpoint inhibitor\u2013associated adverse events","volume":"16","author":"Adam","year":"2021","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.906565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T06:58:35Z","timestamp":1655189915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.906565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":74,"alternative-id":["10.3389\/fmed.2022.906565"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.906565","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"article-number":"906565"}}